Key Takeaways
- Electronic patient-reported outcomes (ePRO) are no longer a nice-to-have. The global ePRO market was valued at roughly $843 million in 2023 and is on track to surpass $2.8 billion by 2031, growing at a 16.5% CAGR as pharmaceutical sponsors, providers, and medtech companies abandon paper diaries for mobile-first data capture.
- The clinical case is now backed by survival data. A landmark JAMA-published trial led by Dr. Ethan Basch found that cancer patients who self-reported symptoms through a digital tool lived a median of 5 months longer than those receiving usual care, with 31% more patients in the intervention arm reporting improved quality of life and meaningful reductions in ER visits.
- Building a PRO mobile app is not the same as building a consumer health app. It requires HIPAA-compliant architecture, 21 CFR Part 11 audit trails, BYOD strategies, EHR integration, and clinical workflow design that survives contact with real patients and real providers.
The Symptoms Your Doctor Never Sees
Picture this scenario. A patient walks out of an oncology appointment, gets in the car, and within four hours starts experiencing a wave of nausea, fatigue, and bone pain that will define the next several days of her life. She thinks about calling the clinic, then talks herself out of it. By the time her next infusion rolls around two weeks later, the worst of it has passed. When the nurse asks how she felt since the last visit, she shrugs and says, “Not great, but okay.”
That conversation, repeated millions of times a year, is the quiet failure at the heart of modern medicine. And it is exactly the failure that mobile patient-reported outcomes apps are designed to fix.
Here is the statistic that should stop every healthcare executive in their tracks: clinicians miss up to half of the symptoms their patients experience between visits. That number does not come from a patient advocacy group. It comes from peer-reviewed oncology research, and it has held up across multiple studies and therapeutic areas. When the people who design treatment plans cannot see the lived reality of the people receiving treatment, decisions get made on incomplete information. Side effects escalate. Hospitalizations happen that did not need to happen. Trials produce data that does not reflect what patients actually felt.
The fix is conceptually simple. Give patients a tool on the device they already carry, ask them the right questions at the right times, route the answers to the right person fast enough to matter, and make the whole thing rigorous enough to survive a regulatory audit. The execution is where most projects fall apart.
For businesses considering an investment in a patient-facing healthcare app, understanding what separates a successful PRO platform from an expensive mistake is the difference between accelerating a clinical program and stalling it for 18 months.
What Patient-Reported Outcomes Actually Are
A patient-reported outcome, or PRO, is any health status measure that comes directly from the patient without interpretation by a clinician or anyone else. It is the raw signal: how much pain, how much fatigue, how often the nausea hits, how the fibromyalgia is affecting sleep this week, whether the new biologic is letting her play with her kids again. PROs sit alongside clinician-reported outcomes (what the doctor observes), observer-reported outcomes (what a caregiver notices), and performance outcomes (what a patient can demonstrate on a standardized task) inside the broader category of clinical outcome assessments, or COAs.
When PROs are collected on a smartphone, tablet, web portal, or wearable instead of a paper questionnaire, they become electronic patient-reported outcomes, or ePROs. The “e” matters more than it sounds. Electronic capture eliminates transcription errors, time-stamps every entry so you know exactly when a symptom appeared, enables conditional logic that adapts the next question to the previous answer, and pushes data to a central system the moment a patient hits submit. Paper diaries, by comparison, are notoriously unreliable. Patients fill them out in waiting rooms minutes before appointments, a phenomenon researchers politely call “parking lot compliance.”
The most common PRO use cases fall into three buckets:
Clinical trials. Pharmaceutical sponsors and contract research organizations use ePRO platforms to capture symptoms, side effects, quality of life metrics, and treatment satisfaction from trial participants. In decentralized and hybrid trial designs, ePROs are often the primary mechanism for collecting endpoint data.
Routine clinical care. Health systems deploy PRO apps to monitor cancer patients during chemotherapy, track recovery after orthopedic surgery, manage chronic conditions like diabetes and rheumatoid arthritis, and surface mental health concerns between visits.
Real-world evidence and post-market surveillance. Medtech and pharma companies use PRO data collected after a product has launched to demonstrate value to payers, identify safety signals, and support label expansions.
Each of these contexts has its own regulatory expectations, its own user populations, and its own definition of success. A platform built for one rarely transfers cleanly to another, which is why partnering with a team that has built clinical trial mobile applications across multiple use cases tends to save sponsors months of rework.
The Market Is Moving Fast, and It Is Moving Mobile
The numbers behind the ePRO category are eye-catching even by digital health standards. Multiple research firms have pegged the global ePRO market at somewhere between $840 million and $1.5 billion in 2023, depending on how the segment is defined, with growth rates clustering between 15% and 17% annually. The Insight Partners projects the ePRO market will reach roughly $2.87 billion by 2031. Towards Healthcare estimates the broader electronic clinical outcome assessment market will climb from about $1.97 billion in 2024 to $8.77 billion by 2034, with ePROs accounting for the majority share.
In the United States alone, FactMR estimates the ePRO, e-patient diaries, and eCOA market reached more than $3.6 billion in 2024, with electronic patient-reported outcomes representing more than 70% of that total.
What is driving the surge?
First, decentralized clinical trials are no longer a pandemic experiment. Sponsors learned during COVID-19 that participants could enroll, consent, and report from home, and that doing so dramatically improved recruitment and retention, especially for rare disease and underrepresented populations. ePRO is the connective tissue that makes those trial designs work.
Second, regulators are not just allowing electronic capture, they are encouraging it. The FDA, EMA, and MHRA have all issued guidance pushing sponsors toward digital outcome assessment, particularly for endpoints where the patient’s own report is the most valid source of truth. The FDA’s Patient-Focused Drug Development guidance has effectively made high-quality PRO data a competitive necessity in submissions across oncology, neurology, and dermatology.
Third, payers and health systems facing value-based reimbursement need objective evidence that a treatment is doing what it claims. PROs are increasingly written into quality measures, alternative payment models, and Medicare’s oncology demonstrations. If a hospital cannot show that patients on a given protocol are actually feeling better, the dollars start moving elsewhere.
Fourth, the underlying technology has finally caught up. Smartphones are nearly universal across all age groups in developed markets. Cloud infrastructure is cheap, secure, and HIPAA-compliant out of the box. Wearables can passively contribute objective data alongside the subjective patient report. Bring-your-own-device (BYOD) is now table stakes rather than a research curiosity. In August 2024, Statistics & Data Corporation launched its own BYOD ePRO solution explicitly framed as a way to eliminate paper and expand participant access. Similar announcements have followed from Clinical Ink, YPrime, and uMotif.
Fifth, AI is starting to do useful work. The ePRO analytics with AI segment alone was valued at $1.58 billion in 2024 and is projected to grow to $3.25 billion by 2029, according to ResearchAndMarkets. AI is being used to flag concerning symptom trajectories, generate adaptive questionnaires that shorten patient burden, and detect data quality issues in near real time.
Put it all together and you have a category that has matured from “interesting idea” to “default standard” in less than a decade. Businesses that have not yet committed to a digital PRO strategy are now playing catch-up against competitors who are already on their second or third generation of platform.
The Survival Data That Changed the Conversation
For years, the case for ePRO rested on intuition and operational arguments. It is faster. It is cleaner. It feels more modern. Then Dr. Ethan Basch and his colleagues at Memorial Sloan Kettering published a randomized trial that turned the conversation upside down.
The study enrolled 766 patients receiving outpatient chemotherapy for metastatic solid tumors. Half were assigned to usual care. The other half were given access to a web-based tool that prompted them to self-report 12 of the most common cancer treatment symptoms, with automatic email alerts sent to nurses when symptoms worsened. Nurses then took action on those alerts roughly three out of four times, adjusting medications, providing counseling, or escalating care.
The quality-of-life results were impressive on their own. At six months, 31% more patients in the intervention group reported improved quality of life compared with those in usual care. Patients in the ePRO arm also had 7% fewer emergency room visits and were able to remain on chemotherapy for nearly two months longer than those in usual care.
Then came the survival data. Median overall survival in the intervention group was 31.2 months, compared with 26 months in the usual care group. That is a five-month difference, achieved not through a new drug or a new surgical technique, but by making it easier for patients to tell their care team how they were actually feeling.
A senior ASCO expert put it bluntly at the 2017 conference where the data were presented: if a drug had produced this kind of survival advantage, it would be priced at $100,000 a year and rolled out across every cancer center in the country. Instead, it was a software intervention. A 2024 systematic review and meta-analysis published in JAMA Network Open looked at 45 randomized trials of PRO measures in cancer care and concluded with moderate certainty that integrating PROMs likely improves both overall survival and short-term health-related quality of life. The same meta-analysis noted that pooled reductions in emergency department visits and hospitalizations did not reach statistical significance, a reminder that the operational benefits seen in individual trials do not always replicate cleanly across heterogeneous study designs.
This is the rare digital health story where the clinical evidence has actually moved faster than the marketing. For pharmaceutical companies building label claims, for health systems negotiating value-based contracts, and for medtech firms documenting post-market performance, that body of evidence is now impossible to ignore.
What a Real PRO Mobile App Has to Do
The temptation, especially for businesses new to the healthcare space, is to think of a PRO app as a glorified survey tool. Build a few questionnaires, add a login screen, push notifications for reminders, ship it. That approach almost always produces an app that fails its first compliance review or its first patient cohort, whichever comes first.
A production-grade PRO mobile app needs to handle, at minimum, the following:
Validated instruments rendered exactly as designed. PRO measures like the EORTC QLQ-C30, PROMIS short forms, FACT-G, and condition-specific instruments are copyrighted, validated tools. They have to be displayed with the right wording, in the right order, with the right response options, and in the right languages. A single dropped item or rephrased question can invalidate the data. Most platforms require either licensed access to instrument libraries or formal validation studies for adapted versions.
Branching logic and skip patterns. Real questionnaires are not flat lists. If a patient reports she has not had nausea, she should not be asked to rate its severity. If she reports severe pain, she should be routed into a follow-up sequence that captures location, duration, and rescue medication use. This logic has to be tested rigorously across every device the app supports.
Time-windowed assessments. Many PRO instruments are designed to be completed within a specific window, often a 24- or 48-hour period after a stimulus like a chemotherapy infusion. The app has to enforce those windows, prevent backdating, and generate compliant audit trails when patients miss them.
Notifications that respect human beings. Push notifications are the make-or-break feature for compliance, but they are also the fastest way to make patients delete an app. The best platforms tune notification frequency based on patient behavior, allow customization, and back off gracefully when a patient is clearly overwhelmed.
Offline mode. Patients on chemotherapy do not always have reliable connectivity. A platform that loses data when a patient submits a diary entry from a basement infusion suite is not a serious clinical tool.
Multi-language and accessibility support. Trials run globally. Patient populations include the elderly, the visually impaired, and people with cognitive limitations from disease or treatment. Font scaling, screen reader support, large touch targets, and high-contrast color schemes are not optional features. They are core requirements.
Clinician dashboards and alerting. The patient app is only half of the system. On the back end, providers need a dashboard that shows symptom trends, flags concerning thresholds, integrates with the electronic health record, and routes alerts to the right person at the right time. Without that loop, the app collects data that nobody acts on, which means patients learn quickly that filling it out is pointless.
Integration with everything else. A modern ePRO platform typically needs to talk to electronic data capture (EDC) systems for trials, EHRs for clinical care, FHIR-based interoperability layers, wearables and sensors for passive data, and analytics warehouses for downstream reporting. Each of those integrations is its own subproject, and each one tends to expose architectural assumptions that should have been questioned earlier.
This list is not exhaustive. It is just enough to make clear why businesses tend to underestimate the scope of these projects by half or more. The teams that build these apps successfully are usually teams that have built medical device companion apps or remote monitoring platforms before, and have a working relationship with clinical and regulatory specialists from day one.
The Compliance Stack You Cannot Avoid
PRO apps live inside one of the most heavily regulated environments in software. The compliance requirements vary based on use case, but most projects need to satisfy some combination of the following:
HIPAA in the United States, which governs the handling of protected health information for any app used in clinical care or for trials with US sites. HIPAA requires technical safeguards (encryption at rest and in transit, access controls, audit logging), administrative safeguards (workforce training, breach response plans, business associate agreements), and physical safeguards for any infrastructure that touches PHI.
21 CFR Part 11 for electronic records and electronic signatures used in FDA-regulated trials. Part 11 requires validated systems, time-stamped audit trails, secure user authentication, and the ability to generate accurate copies of records for inspection. It is the single most common reason that consumer-grade survey tools fail in trial settings.
GDPR for any participants in the European Union, which adds requirements around lawful basis for processing, data subject rights, cross-border transfers, and data protection impact assessments.
ICH E6 (R3) Good Clinical Practice, the international standard for clinical trial conduct, which expects sponsors to maintain control over trial data and processes including those mediated by digital tools.
FDA guidance on Software as a Medical Device (SaMD). Most ePRO tools used purely for data collection are not regulated as medical devices, but tools that interpret data, drive treatment decisions, or claim therapeutic effects can cross the line into SaMD territory and require a 510(k) or De Novo submission.
State telemedicine and licensing rules for any app that facilitates clinical communication across state lines.
ISO 27001 for information security management, often required by enterprise customers and increasingly by sponsors.
ISO 13485 design controls for any platform supporting regulated device or pharmaceutical development.
The cost of getting compliance right is significant. The cost of getting it wrong is bigger. Every quarter, the FDA publishes warning letters and the FTC publishes enforcement actions against companies that mishandled health data, and the financial and reputational damage is rarely recoverable. Compliance has to be designed into the architecture from the first sprint, not bolted on before launch.
This is the area where partner selection matters most. Engineers who have not worked inside a regulated environment do not know what they do not know, and the gap shows up six months in when somebody finally reads the protocol and discovers that the data store cannot generate the audit trail the sponsor needs.
The Implementation Pitfalls Nobody Talks About in the Sales Deck
Even teams that get the technology right run into a predictable set of problems once real patients start using the app. A few of the most common:
Recall bias and “parking lot compliance” carry over from paper. Patients learn quickly that they can fill out three days of entries in five minutes during a wait. Good platforms enforce assessment windows and prevent backfilling, but doing so takes design discipline and a willingness to lose some data rather than collect bad data.
Notification fatigue kills engagement faster than anything else. A patient who gets six pings a day during the worst week of chemotherapy will stop engaging. The fix is intelligent throttling, contextual timing, and giving patients meaningful control over how they are contacted.
The user interface assumes a healthy, tech-fluent user. The actual user is often elderly, exhausted, in pain, on medications that affect concentration, and using a six-year-old phone with a cracked screen. Platforms that have not been usability-tested with the actual patient population will fail in the field.
Site and provider buy-in gets ignored. ePRO data only matters if somebody acts on it. If clinic workflows are not redesigned to incorporate the alerts, nurses will turn off notifications inside the first month and the app becomes shelfware.
EHR integration is harder than it sounds. Every health system configures Epic, Cerner, or Allscripts differently. FHIR APIs help, but custom mapping work is almost always required, and that work tends to add 2 to 4 months to project timelines that did not budget for it.
Patient consent is more than a checkbox. Informed consent in a digital trial environment has to handle electronic signatures, multiple languages, comprehension verification, and the ability to withdraw consent gracefully. Done poorly, it becomes a recruitment bottleneck.
Translation and cultural adaptation are not optional for global trials. A literal translation of a PROMIS short form into Mandarin is not the same as a culturally adapted, linguistically validated version. Sponsors who skip the validation step end up with data they cannot pool across sites.
These are not exotic edge cases. They are the standard challenges that every PRO project encounters, and the difference between an experienced development team and a first-timer is mostly about how many of these landmines have already been stepped on.
Use Cases That Are Already Working
The clearest way to understand where PRO mobile apps create business value is to look at where they are already deployed at scale.
Oncology symptom monitoring. This is the most mature use case, anchored by the Basch trial and a wave of follow-on implementations. Health systems use PRO platforms to track chemotherapy side effects between visits, route alerts to triage nurses, and intervene before symptoms escalate to ER visits. The clinical evidence is strong enough that the use case is now being written into value-based payment models.
Decentralized and hybrid clinical trials. Pharmaceutical sponsors and CROs use ePRO platforms to capture endpoint data from participants who are enrolled remotely or who travel infrequently to clinical sites. Decentralized designs improve recruitment, especially for rare diseases and underserved populations, but only if the data capture infrastructure is reliable.
Orthopedic recovery tracking. Joint replacement programs use PRO measures like the HOOS and KOOS to track functional recovery after hip and knee surgery. The data feeds bundled payment programs and identifies patients who need additional physical therapy or follow-up.
Mental health monitoring. Behavioral health programs deploy validated instruments like the PHQ-9 and GAD-7 through mobile apps to track depression and anxiety symptoms between sessions. The trend lines are often more clinically useful than single in-session snapshots.
Chronic disease management. Programs in diabetes, heart failure, COPD, and inflammatory bowel disease use PRO apps to capture symptom diaries, medication adherence, and quality-of-life measures over months and years.
Rare disease registries. Patient advocacy organizations and pharmaceutical sponsors use mobile PRO platforms to build natural history databases for rare conditions where geographically dispersed populations make traditional research impractical.
Post-market surveillance. Medical device companies use PRO data collected from real-world users to monitor product performance, identify safety signals, and support label expansions. Combining ePRO with passive data from connected wearable devices creates a particularly rich evidence base.
In each of these contexts, the business case rests on the same foundation: better data, captured at the right moment, in the patient’s own voice, fed into decisions that change outcomes.
How Much Does It Cost and How Long Does It Take?
Sponsors and product teams ask these questions on every initial call, and the honest answer is that it depends on a small number of variables that swing the budget by an order of magnitude.
Build complexity sits at the top of the list. Based on industry experience and published ranges from healthcare app development teams, a single-instrument symptom diary with a simple clinician dashboard and BYOD support can typically be delivered in the range of $150,000 to $300,000 over four to six months. A multi-instrument, multi-language, EHR-integrated platform supporting a global trial with medical-grade compliance more commonly runs $500,000 to $1.5 million or more over 9 to 18 months. A platform designed for SaMD classification with FDA submission support can climb beyond that. These are ballpark figures rather than fixed quotes, and actual costs vary significantly based on the specifics of any given build.
Other cost drivers include:
- Number of validated instruments. Each one requires licensing, formatting, validation, and testing.
- Number of supported languages. Each language requires linguistic validation, not just translation.
- Integration scope. EHR, EDC, wearables, identity providers, and analytics warehouses each add integration work.
- Regulatory pathway. A non-SaMD data collection tool is dramatically simpler than a regulated decision-support tool.
- Operational support. Most projects underbudget for the ongoing site training, helpdesk, and content updates that keep the platform functional after launch.
- Cross-platform requirements. Native iOS and Android with full offline support cost more than a single platform or a hybrid framework.
The biggest budget mistake is treating the launch as the finish line. Healthcare apps are living systems, and the maintenance, support, and iteration work in years two and three is often comparable to the original build cost. Sponsors who plan for that reality are happier with the result.
Choosing a Development Partner
Most businesses building a PRO mobile app will not staff up a full in-house development team. They will partner with a mobile app development firm that brings the technical, design, and regulatory experience the project needs. Partner selection is the single most consequential decision in the project, and the wrong choice is expensive to undo.
A few questions worth asking any prospective partner:
- How many healthcare apps have you actually shipped, and how many of them touched regulated environments?
- Can you walk through a specific HIPAA implementation you completed end to end?
- Have you supported a sponsor through a 21 CFR Part 11 audit?
- What is your experience with EHR integration, and what therapeutic areas have you worked in?
- Who on your team has clinical or regulatory background, and how are they involved in the build?
- Can you provide references from healthcare clients who can speak to compliance work specifically?
- What is your post-launch support model?
Lowest bidder is usually the wrong answer. Compliance rework on a healthcare app discovered late in development can cost more than the original build, and the lost time can derail a clinical program entirely. The right partner is one who has stepped on enough of the landmines listed earlier to recognize them before they go off.
Dogtown Media has spent more than a decade building healthcare and clinical mobile applications for clients ranging from global pharmaceutical companies and major academic medical centers to digital health startups and patient advocacy organizations. The team’s experience with HIPAA-compliant architecture, FDA regulatory pathways, EHR integration, and remote patient monitoring gives sponsors a partner who understands both the technical and clinical sides of the equation. For businesses ready to scope a PRO platform or modernize an existing data capture workflow, the healthcare app development team brings the domain expertise that turns a good idea into a compliant, deployable product.
What the Next Five Years Look Like
The PRO mobile app category is not standing still. A few of the trends worth watching:
AI-powered analytics will move from dashboards to decision support. The ePRO analytics with AI segment is growing at roughly 15% annually, and the use cases are shifting from descriptive (what happened) to predictive (which patients are at risk) and prescriptive (what should the care team do next). Sponsors who build platforms that can plug into AI workflows will have a meaningful advantage.
Passive data from wearables will become standard. Pairing patient-reported symptoms with passively collected heart rate, sleep, activity, and respiratory data creates a much richer signal than either source alone. Apple Watch, Fitbit, Whoop, Oura, and a growing list of medical-grade wearables are now common inputs to clinical PRO platforms.
BYOD will become the default, not the exception. The shift from sponsor-provided devices to bring-your-own-device strategies dramatically reduces operational overhead and improves participant engagement. The remaining barriers are around device fragmentation and equity of access, both of which are getting easier to solve.
Decentralized and hybrid trials will keep growing. The pandemic accelerated a transition that was already underway, and the operational and recruitment advantages have proven durable. ePRO is the connective tissue that makes those designs work.
Regulators will continue tightening expectations. The FDA’s Patient-Focused Drug Development program and the EMA’s parallel initiatives are pushing sponsors toward higher-quality PRO data, more transparent measurement strategies, and better integration of patient voice into label claims.
Voice and conversational interfaces will reduce burden. Natural language interfaces are starting to appear in clinical assessment tools, and the technology has matured enough that it can reduce the cognitive burden on patients while improving data quality.
Interoperability standards will get serious. FHIR-based data exchange is now mature enough to be the default for new builds, and CDISC standards continue to evolve to handle ePRO data structures.
The platforms being built today will be the foundation for the next generation of clinical research, value-based care, and real-world evidence generation. The businesses that invest now will be in a much stronger position when the regulatory and reimbursement environment tightens further.
The Bottom Line
A patient-reported outcomes mobile app is not a survey tool with a logo. It is a clinical instrument, a regulatory artifact, and a piece of software infrastructure that has to work for patients, providers, regulators, and sponsors all at the same time. The businesses that get it right are the ones that take both the clinical evidence and the engineering complexity seriously from day one.
The market opportunity is real and growing fast. The clinical evidence is now compelling enough that holding out feels increasingly indefensible. The technology is mature, the regulatory pathways are clear, and the partner ecosystem has caught up to the demand. What remains is the willingness to commit to a build that is harder than it looks, with a team that has done it before.
For pharmaceutical sponsors, CROs, health systems, medtech companies, and digital health startups thinking through how to bring patient voice into their products and programs, the next five years will reward the teams that move now. The ones that wait for the category to “settle down” will spend the back half of the decade trying to catch up to competitors who are already collecting the data.
Frequently Asked Questions
What is the difference between PRO and ePRO? A patient-reported outcome (PRO) is any health status measure reported directly by the patient without interpretation by a clinician. An electronic patient-reported outcome (ePRO) is a PRO collected through a digital tool such as a mobile app, web portal, tablet, or wearable. ePROs eliminate transcription errors, time-stamp every entry, and enable real-time alerting and analytics that paper-based collection cannot support.
Are PRO mobile apps regulated as medical devices? Most PRO apps used purely for data collection are not regulated as medical devices. They are tools that capture patient input and route it to clinical or research teams. However, an app that interprets the data, drives treatment decisions, or claims a therapeutic effect can cross into Software as a Medical Device (SaMD) territory and require an FDA 510(k), De Novo, or PMA submission. The line is fact-specific, and the regulatory pathway should be clarified early in development.
How does HIPAA apply to a PRO app? HIPAA applies to any PRO app that collects, stores, or transmits protected health information for use in clinical care or in clinical trials with US sites. Compliance requires encrypted storage and transmission, audit logging, access controls, workforce training, breach response plans, and signed business associate agreements with any vendors that handle PHI. HIPAA compliance has to be designed into the system architecture from the start, not added later.
What is 21 CFR Part 11 and why does it matter for ePRO? 21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures used in FDA-regulated activities, including clinical trials. For ePRO platforms, Part 11 requires validated systems, time-stamped audit trails, secure authentication, the ability to detect unauthorized changes, and accurate record retrieval for inspection. Consumer-grade survey tools almost never meet these requirements, which is why purpose-built ePRO platforms are the standard for trial use.
How long does it take to build a PRO mobile app? Timelines vary significantly based on complexity. A focused symptom diary with a single instrument and basic clinician dashboard might be deliverable in four to six months. A full ePRO platform supporting a global trial with multiple instruments, languages, EHR integration, and Part 11 compliance typically takes 9 to 18 months. SaMD-classified tools requiring FDA submission can take longer.
What does a PRO mobile app cost to build? Budgets vary widely. As a general benchmark, focused builds typically fall in the $150,000 to $300,000 range, while full clinical-grade platforms with multiple instruments, languages, integrations, and Part 11 compliance more often run $500,000 to $1.5 million or more. Cost drivers include the number of validated instruments, supported languages, integration scope, regulatory pathway, and ongoing operational support. Underbudgeting for post-launch maintenance is one of the most common project mistakes.
Can PRO apps integrate with existing EHR systems? Yes, and increasingly they have to. FHIR APIs make modern EHR integration cleaner than it used to be, but every health system configures Epic, Cerner, or Allscripts differently, and custom mapping work is almost always required. Sponsors should expect EHR integration to add two to four months to project timelines and should involve health system IT teams from the planning phase.
What is BYOD and why does it matter? BYOD stands for “bring your own device,” meaning patients use their own smartphones or tablets to participate in a study or care program rather than receiving a sponsor-provided device. BYOD dramatically reduces operational overhead, improves participant engagement, and makes trials more accessible. The trade-offs are device fragmentation, varying screen sizes and operating system versions, and equity-of-access concerns for participants without modern smartphones.
How do PRO apps handle non-English speaking patients? Through linguistic validation, not literal translation. PRO instruments validated in English have to go through a formal translation and back-translation process, followed by cognitive debriefing with native speakers, before they can be used in another language. Cutting corners here invalidates the data and makes pooling across sites impossible.
What clinical evidence supports the use of ePRO in cancer care? The strongest evidence comes from a randomized trial led by Dr. Ethan Basch and colleagues, published in JAMA, which found that cancer patients who reported symptoms electronically lived a median of 5 months longer than those receiving usual care, with significant improvements in quality of life and reductions in ER visits. A 2024 systematic review and meta-analysis in JAMA Network Open of 45 randomized trials concluded with moderate certainty that integrating PRO measures into cancer care likely improves both overall survival and short-term quality of life.
